- Acumen Powered by Robins Kaplan LLP™
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
July 27, 2021Robins Kaplan Secures $19.5M Settlement for Indirect Buyers in Interior Molded Doors Antitrust Litigation
-
July 21, 2021Benchmark Litigation Names Patrick Arenz and Aaron Fahrenkrog to its 40 & Under Hot List in 2021
-
July 20, 2021Five Robins Kaplan Firm Members Recognized by Minnesota Lawyer
-
August 5, 2021Domesticating an Out of State Judgment in The State of Florida
-
August 6, 2021Mastering the Deposition: 30(b)(6) Deposition Strategies and Updates 2021
-
August 19, 2021Annual Robins Kaplan MAJ Reception
-
Second QuarterANDA Litigation Settlements
-
Second QuarterNew ANDA Cases
-
Second QuarterANDA Approvals
-
July 28, 2021Financial Daily Dose 7.28.2021 | Top Story: Big Tech Reports Massive Q2 Results
-
July 27, 2021Financial Daily Dose 7.27.2021 | Top Story: Insurance Giants Aon and Willis Towers Watson Call Off Planned Merger After DOJ Pushback
-
July 26, 2021Financial Daily Dose 7.26.2021 | Top Story: Top Crypto Exchanges Limit Leverage to Curb Risk
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Judge Rules Collegium Pharmaceutical Inc. Does Not Infringe Two OxyContin Patents
October 1, 2018
A Massachusetts federal judge recently ruled that Robins Kaplan client Collegium Pharmaceutical Inc. did not infringe upon two of Purdue Pharma LP’s OxyContin-related patents. The ruling represents a significant victory for Collegium and its two-year-old drug, Xtampza XR.
Law360 covered the ruling in a recent article:
Xtampza Not Infringing 2 OxyContin Patents, Judge Says
All Content © 2018, Portfolio Media, Inc.
Related Publications
July 15, 2021
Biotechnology & Trade Secret Protection
Sharon Roberg-Perez, David Prange, Ellen Levish - Bloomberg Law
June 8, 2021
Written Description in the Life Sciences: The Devil is in the Details
Sharon Roberg-Perez, William Jones - IPWatchdog
May 5, 2021
Bio-Rad Ruling Highlights IP Assignment Clause Limits
Bryan J. Vogel, Derrick J. Carman - Law360
April 20, 2021
Copyright Concerns For NFT Buyers, Sellers In Music Industry
Carly Kessler - Law360
March 26, 2021
Trends In Video Game Company Quests To Arbitrate Cases
Matthew Woods, Austin Miller - Law360
Related News
July 21, 2021
June 16, 2021
May 20, 2021
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.